Endometriosis – our new study reveals trends, R&D progress, and predicted revenues Where is the Endometriosis market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.
Discover How to Stay Ahead Our 146-page report provides 108 tables, charts, clearly illustrating the data presented in this research. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted drug sales at overall world market regional level, as well as giving a deep insight into the pipeline for Endometriosis. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Endometriosis market. See how to exploit the opportunities.
Forecasts to 2027 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2027, our new study provides you with recent results, R&D overview, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and following Endometriosis Therapeutics: • Lupron • Eligard • Zoladex • Depo-Provera • Visanne
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 11 leading national markets: • The US • Germany • France • The UK • Spain • Italy • Japan • China • India • Brazil • Russia • RoW
The report also includes profiles and pipeline analysis for some of the leading companies in the Endometriosis market, with a focus on the Endometriosis segment of these companies’ operations.
There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, Germany, France and India in particular, will continue to achieve high revenue growth to 2027.
Leading companies and the potential for market growth Overall world revenue for Endometriosis will surpass $3bn in 2027, our work calculates. This will be driven by the development of more effective drugs for the condition as well as raising awareness of Endometriosis over the forecast period
Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Endometriosis Market report helps you In summary, our 146-page report provides you with the following knowledge: • Revenue forecasts to 2027 for the Endometriosis market and 5 Leading Therapeutic Drugs for the condition – discover the industry’s prospects, finding the most lucrative places for investments and revenues • Revenue forecasts to 2027 for 11 of the leading national markets – US, Germany, France, UK, Italy, Spain, Russia, Japan, China, India, Brazil • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market – including company profiles and R&D overviews for 10 companies involved in developing and manufacturing Endometriosis drugs
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the Endometriosis market and leading companies. You will find data, trends and predictions.
Get our report today Endometriosis Drug Forecasts and R&D 2017-2027: Forecasts and Analysis of Leading Endometriosis Drugs (Lupron, Eligard, Zoladex, Depo-Provera, Visanne), Companies and Key National Markets. Avoid missing out – get our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1. Endometriosis Drugs: Industry and Market Review 1.2. Benefits of This Report 1.3. How This Study Delivers 1.4. Main Questions This Work Answers 1.5. Who is This Report For? 1.6. Methods of Research and Analysis 1.7. Frequently Asked Questions (FAQ) 1.8. Some Related Visiongain Reports 1.9. About Visiongain
2. Introduction to Endometriosis and its Treatment 2.1. What is Endometriosis? 2.2. Incidence and Prevalence of Endometriosis 2.3. The Endometriosis Drug Market, 2016 2.4. PEST Analysis 2.4.1. Political Factors 2.4.2 Economic Factors 2.4.3 Social Factors Affecting the Endometriosis Therapies Market 2.4.4 Technological Developments in Endometriosis Treatment 2.5 Market Growth Drivers and Restraints 2.6 Outlook for the Endometriosis Drugs Market, 2016-2027
3. Leading National Markets: Outlooks, 2017-2027 3.1 Endometriosis Treatment by Therapy 3.1.1. Hormones 3.1.2. Painkillers 3.1.3. Surgical Treatment
4. Endometriosis Leading National Markets, 2017-2027 4.1. Leading National Markets: The US Dominated in 2016 4.1.1. What is The Future for Leading National Markets? 4.2. The US Endometriosis Market, 2017 to 2027 4.3. EU5 Endometriosis Market, 2017 to 2027 4.3.1. The UK Endometriosis Market, 2017 to 2027 4.3.2. French Endometriosis Market, 2017 to 2027: Steady Growth throughout the Forecast Period 4.3.3. German Endometriosis Market, 2017 to 2027: Largest Market Share in European Union 4.3.4. Spanish Endometriosis Market, 2017 to 2027 4.3.5. Italian Endometriosis Market, 2017 to 2027 4.4. Japanese Endometriosis Market, 2017 to 2027: Second Largest Market in the World 4.5. Chinese Endometriosis Market, 2017 to 2027 4.6. Indian Endometriosis Market, 2017 to 2027: Fast Growing Market 4.7. Brazilian Endometriosis Market, 2017 to 2027 4.8. Russian Endometriosis Market, 2017 to 2027
5. Leading Drugs in World Endometriosis Market, 2016 5.1. Lupron: One of the Leading Endometriosis Drug in the Market 5.1.1. Profile 5.1.2. Lupron Historical Revenue 5.1.3. Lupron Revenue Forecast, 2017-2027 5.2. Eligard: Facing Challenges When Patent Expires 5.2.1. Profile 5.2.2. Eligard Historical Revenue 5.2.3. Eligard Revenue Forecast, 2017-2027 5.3. Zoladex 5.3.1. Profile 5.3.2. Zoladex Historical Revenue 5.3.3. Zoladex Revenue Forecast, 2017-2027 5.4. Depo-Provera 5.4.1. Profile 5.4.2. Depo-Provera Historical Revenue 5.4.3. Depo-Provera Forecast, 2017 to 2027 5.5. Visanne: First Oral Treatment for Endometriosis by Bayer 5.5.1. Profile 5.5.2. Visanne Historical Revenue 5.5.3. Visanne Forecast, 2017 to 2027
6. Research and Development for Endometriosis Drugs 6.1. Industry Collaboration and R&D Activities 6.1.1. Investigational Drug Treatment for Endometriosis 6.2. Companies Involved in Producing Drugs for Endometriosis 6.3. AbbVie: Leading Producer of Endometriosis Drugs 6.3.1. Company Description 6.3.2. Business Segmentation 6.3.3. AbbVie Revenue Performance, 2016 6.3.4. Product in Pipeline: Elagolix, Oral Drug 6.4. Pfizer 6.4.1. Company Description 6.4.2. Business Segmentation 6.4.3. Pfizer Revenue Performance, 2016 6.5. Bayer HealthCare: Visanne Showing Faster Growth in Revenue 6.5.1. Company Description 6.5.2. Business Segmentation 6.5.3. Bayer HealthCare Revenue Performance, 2016 6.5.4. Four Drug Candidates in Product Pipeline 6.6. AstraZeneca 6.6.1. Company Description 6.6.2. Business Segmentation 6.6.3. AstraZeneca Revenue Performance, 2016 6.7. Astellas 6.7.1. Company Description 6.7.2. Business Segmentation 6.7.3. ASP1707 an Oral Dosage Form: Product in Pipeline 6.8. Takeda 6.8.1. Company Description 6.8.2. Business Segmentation 6.8.3. Product in Pipeline: Relugolix- Oral Form 6.9. Repros Therapeutics Inc. 6.9.1. Company Description 6.9.2. Business Segmentation 6.9.3. Product in Pipeline: Proellex in Phase II Trials 6.10. Euroscreen S.A. 6.10.1. Company Description 6.10.2. Business Segmentation 6.10.3. Product in Pipeline: ESN364 Completes Enrolment in Phase II Trials 6.11. Kissei Pharmaceutical 6.11.1. Company Description 6.11.2. Business Segmentation 6.11.3. Product in Pipeline: KLH-2109 Exclusive Rights Given to ObsEva 6.12. Addex Therapeutics 6.12.1. Company Description 6.12.2. Product in Pipeline
7. Qualitative Analysis of Endometriosis Drugs Market 7.1. SWOT Analysis: Future Scope of The Market 7.2. Strengths of The Market 7.2.1. Vast, Expanding Ageing Population 7.2.2. A Number of Promising Drug Candidates 7.2.3. Secondary Indications 7.3. Weaknesses 7.3.1. Lack of Disease Awareness 7.3.2. Reimbursement Issues 7.3.3. Demand for Better Diagnosis and Treatment of Endometriosis 7.4. Opportunities 7.4.1. Rising Disease Prevalence 7.4.2. Increased Demand in Market 7.4.3. Novel Mechanisms and Delivery Methods 7.5. Threats 7.5.1. Competition from Generic Drugs 7.5.2. Governments Limiting Healthcare Spending
8. Conclusions from the Research and Analysis 8.1. Future of the Endometriosis Pharmaceuticals Market 8.2. The US Will Remain The Largest National Market From 2017 to 2027 8.3. Trends in the Endometriosis Treatments Market
9. Glossary Associated Visiongain Reports Visiongain Report Sales Order Form Appendix A About Visiongain Appendix B Visiongain Report Evaluation Form
List of Figures in this Report Figure 2.1 Prevalence of Endometriosis in Women (in Millions), Leading Countries, 2016 Figure 2.2 Global Endometriosis Market Revenue Performance: Revenue ($bn), 2014-2016 Figure 2.3 Global Endometriosis Market: Drivers and Restraints, 2017-2027 Figure 2.4 Forecast Global Endometriosis Market: Revenue ($m), 2016-2027 Figure 4.1 Endometriosis Leading National Markets: Shares (%), 2016 Figure 4.2 Endometriosis Leading National Markets: Shares (%), 2016 Figure 4.3 Endometriosis Leading National Markets: Shares (%), 2022 Figure 4.4 Endometriosis Leading National Markets: Shares (%), 2027 Figure 4.5 The US Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 4.6 EU5 Endometriosis Therapeutic Market: Overall Revenue ($m), 2016-2027 Figure 4.7 EU5 Endometriosis Therapeutic Markets: National Shares (%), 2016, 2022 and 2027 Figure 4.8 EU5 Endometriosis Therapeutic Market Forecast: Revenue ($m) Breakdown by Countries, 2016-2027 Figure 4.9 The UK Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 4.10 French Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 4.11 German Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 4.12 Spanish Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 4.13 Italian Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 4.14 Japanese Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 4.15 Chinese Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 4.16 Indian Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 4.17 Brazilian Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 4.18 Russian Endometriosis Therapeutic Market Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 5.1 Endometriosis Drug Market: Revenue ($m) by Leading Drug, 2016 Figure 5.2 Endometriosis Drug Market: Revenue Share (%) by Leading Drugs, 2016 Figure 5.3 Endometriosis Drug Market: Revenue Share (%) by Leading Drugs, 2022 Figure 5.4 Endometriosis Drug Market: Revenue Share (%) by Leading Drugs, 2027 Figure 5.5 Lupron Revenue Segmentation: Revenue Share (%), 2016 Figure 5.6 Lupron Historical Revenue ($m), 2011-2016 Figure 5.7 Lupron Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 5.8 Eligard Revenue Segmentation: Revenue Share (%), 2016 Figure 5.9 Eligard Historical Revenue ($m), 2011-2016 Figure 5.10 Eligard Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 5.11 Zoladex Revenue Segmentation: Revenue Share (%), 2016 Figure 5.12 Zoladex Historical Revenue ($m), 2011-2016 Figure 5.13 Zoladex Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 5.14 Depo-Provera Revenue Segmentation: Revenue Share (%), 2016 Figure 5.15 Depo-Provera Historical Revenue ($m), 2011-2016 Figure 5.16 Depo-Provera Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 5.17 Visanne Historical Revenue ($m), 2011-2016 Figure 5.18 Visanne Forecast: Revenue ($m) and AGR (%), 2016-2027 Figure 6.1 AbbVie: Therapeutic Focus Areas, 2016 Figure 6.2 AbbVie: Revenue Share (%) for Lupron, 2016 Figure 6.3 Pfizer: Revenue ($m) by Business Segment, 2016 Figure 6.4 Pfizer: Revenue Share (%) by Business Segment, 2016 Figure 6.5 Bayer: Revenue Share (%) by Drugs, 2016 Figure 6.6 Bayer: Revenue Share ($m) by Drugs, 2016 Figure 6.7 AstraZeneca: Revenue ($m) by Segment, 2016 Figure 6.8 AstraZeneca: Revenue Share of Drugs (%), 2016 Figure 6.9 AstraZeneca: Revenue ($m) by Drugs, 2016
List of Tables in this Report Table 1.1 Endometriosis Drug Sales: Leading National Markets, Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 1.2 Foreign Currency Exchange Rate to $US, 2016 Table 2.1 Prevalence of Endometriosis in Women: Leading Countries, 2016 Table 2.2 Global Endometriosis Market Revenue Performance: Revenue ($bn) and AGR (%), 2014-2016 Table 2.3 Political, Economic, Social and Technological Forces (PEST) Affecting Endometriosis Market, 2016 Table 2.4 Global Endometriosis Market: Revenues ($m), Annual Growth Rate (%), CAGR (%), 2016-2022 Table 2.5 Global Endometriosis Market: Revenues ($m), Annual Growth Rate (%), CAGR (%), 2022-2027 Table 4.1 Endometriosis Leading National Markets: Revenue ($m) and Market Share (%), 2016 Table 4.2 Endometriosis Leading National Markets Forecast: Revenue ($m), AGR (%) and CAGR (%), 2016-2027 Table 4.3 Market Share (%) and Revenue ($m) Comparison of the Leading Endometriosis Therapeutic National Markets, 2016, 2022 and 2027 Table 4.4 The US Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022 Table 4.5 The US Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027 Table 4.6 EU5 Endometriosis Therapeutic Market Forecasts by Country: Revenue ($m), AGR (%), CAGR (%), 2016-2027 Table 4.7 The UK Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022 Table 4.8 The UK Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027 Table 4.9 Historical and Future Profile of Payment Percentages Table 4.10 French Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022 Table 4.11 French Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027 Table 4.12 German Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022 Table 4.13 German Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027 Table 4.14 Spanish Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022 Table 4.14 Spanish Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027 Table 4.16 Italian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022 Table 4.17 Italian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027 Table 4.18 Japanese Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022 Table 4.19 Japanese Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027 Table 4.20 Chinese Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022 Table 4.21 Chinese Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027 Table 4.22 Indian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022 Table 4.23 Indian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027 Table 4.24 Brazilian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022 Table 4.25 Brazilian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027 Table 4.26 Russian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2016-2022 Table 4.27 Russian Endometriosis Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2022-2027 Table 5.1 The Endometriosis Drug Market: Revenue ($m), Revenue Share (%) by Leading Drugs, 2016, 2022, 2027 Table 5.2 Endometriosis Market: Forecasts by Leading Drugs, Revenue ($m), AGR (%), CAGR (%), 2016-2027 Table 5.3 Lupron Revenue Segmentation: Revenue ($m), Revenue Share (%), 2016 Table 5.4 Lupron Historical Revenue ($m), Annual Growth (%) and CAGR (%), 2011-2016 Table 5.5 Lupron Forecast: Revenue ($m), Annual Growth (%) and CAGR (%), 2016-2027 Table 5.6 Eligard Revenue Segmentation: Revenue ($m), Revenue Share (%), 2016 Table 5.7 Eligard Historical Revenue ($m), Annual Growth (%) and CAGR (%), 2011-2016 Table 5.8 Eligard Forecast: Revenue ($m), Annual Growth (%) and CAGR (%), 2016-2027 Table 5.9 Zoladex Revenue Segmentation: Revenue ($m), Revenue Share (%), 2016 Table 5.10 Zoladex Historical Revenue ($m), Annual Growth (%) and CAGR (%), 2011-2016 Table 5.11 Zoladex Forecast: Revenue ($m), Annual Growth (%) and CAGR (%), 2016-2027 Table 5.12 Depo-Provera Revenue Segmentation: Revenue ($m), Revenue Share (%), 2016 Table 5.13 Depo-Provera Historical Revenue ($m), Annual Growth (%) and CAGR (%), 2011-2016 Table 5.14 Depo-Provera Forecast: Revenue ($m), Annual Growth (%) and CAGR (%), 2016-2027 Table 5.15 Visanne Historical Revenue ($m), Annual Growth (%) and CAGR (%), 2011-2016 Table 5.16 Visanne Forecast: Revenue ($m), Annual Growth (%) and CAGR (%), 2016-2027 Table 6.1 AbbVie: Drug Revenue ($m) and Change (%), 2015 and 2016 Table 6.2 AbbVie: Drug Revenue ($m) and Drug Revenue Share (%), 2016 Table 6.3 Pfizer: Revenue ($m) and Revenue Share (%) Based on Business Segment, 2016 Table 6.4 Bayer: Revenue ($m) and Revenue Share (%) Based on Business Segment, 2016 Table 6.5 Bayer: Drug Revenue ($m) and Drug Revenue Share (%), 2016 Table 6.6 AstraZeneca: Revenue ($m) and Revenue Share (%) Based on Business Segments, 2016 Table 6.7 List of Other Companies in the Endometriosis Market
Abbott Laboratories AbbVie Ablynx NV AC Immune SA Active Biotech AB Addex Therapeutics Ltd. Advanced Biological Laboratories SA AEterna Zenaris Agenus Schweiz AG Agios Pharmaceuticals, Inc. Aileron Therapeutics, Inc. Akari Therapeutics Plc Allergan Plc Amanouchi Pharmaceutical Co. Amgen, Inc. Anacor Pharmaceuticals, Inc. AP Avadis Biotechnologies Apeiron Biologics Ag Apogenix GmbH Aquinox Pharmaceuticals, Inc. ArQule, Inc. Array BioPharma, Inc. Astellas Pharma AstraZeneca Plc Atrix Laboratories Bayer HealthCare BeiGene Ltd. BioAtla LLC Biogen, Inc. BioNTech AG BioPorto A/S Bio-Rad Laboratories, Inc. Celgene Corp. Celmatix Inc. CEL-SCI Corp. Cepheid Cidara Therapeutics, Inc. Cogstate Ltd. Collplant Holdings Ltd. CRISPR Therapeutics AG CTI BioPharma Corp. Cyprotex Plc CytomX Therapeutics, Inc. Debiopharm International Sa DelsiTech Ltd. Domain Therapeutics SA Dongkook Pharmaceutical Co. ElexoPharm GmbH Eli Lilly Enanta Pharmaceuticals, Inc. EndoCeutics Epizyme, Inc. Euroscreen S.A. Euthymics Bioscience Inc. Evotec AG Florida Hospital Fujisawa Pharmaceutical Co. Genentech, Inc. Genzyme Corporation GlaxoSmithKline Halozyme Therapeutics, Inc. HemoShear Therapeutics LLC Highland Clinical Research Hydra Biosciences Inc. Idera Pharmaceuticals, Inc. ImmunoGen, Inc. Immunomedics, Inc. Inc. Forendo Pharma Oy Infinity Pharmaceuticals, Inc. Interleukin Genetics, Inc. Invivo Therapeutics Holdings Corp. Isifer AB Jiangsu Kanion Pharmaceutical Co. Kissei Pharmaceutical Lipicard Technologies Limited Medigene AG Meditrina Pharmaceuticals Medivation, Inc. Mendel Biotechnology Inc. MorphoSys AG Mylan NV Myovant Sciences Ltd. Neurocrine Biosciences, Inc. NextCure Inc. ObsEva OncoMed Pharmaceuticals, Inc. OncoTherapy Science, Inc. OPKO Health, Inc. Orphagen Pharmaceuticals Peptidream Inc. Pfizer Philogen Philogen Spa Portola Pharmaceuticals, Inc. PregLem SA Probiodrug AG pSivida Corp. Puma Biotechnology, Inc. Repros Therapeutics Inc. Roche Sanofi Schering AG SK Chemicals Co. Takeda Pharmaceutical Tolmar Therapeutics ValiRX
Organisations Mentioned in This Report Aljazeera Hospital Australian National University Brigham and Women’s Hospital Centre for Endocrinology and Reproductive Medicine Centre for Epidemiology and Health Research Children’s Hospital Boston Food and Drug Administration (FDA) Highland Clinical Research Indian Brand Equity Foundation Instituto de Investigacion Sanitaria La Fe Jacksonville Centre for Clinical Research Jiangsu Kanion Pharmaceutical Co. Ministry of Health, Labour, and Welfare (Japan) National Health Service National Institute for Clinical Excellence National Institute of Health Northwestern University Northwestern University (Illinois) Research OutSmarts Endometriosis Turku University Hospital University Hospital (Angers) University Hospital (Mo) University Hospital (Mo) University Hospital (Rouen) University of Arhus (Denmark) University of Athens (Greece) University of Cagliari (Italy) University of Illinois University of North Carolina School of Medicine (North Carolina) University of Oxford Women’s Health Care at Frost Street World Endometriosis Research Foundation
Download sample pages
Complete the form below to download your free sample pages for Endometriosis Drug Forecasts and R&D 2017-2027
Download sample pages
Complete the form below to download your free sample pages for Endometriosis Drug Forecasts and R&D 2017-2027
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
